Blossom Pulse Archive
What happened in psychedelic research in 2007
16 events from 2007, dated by when they happened rather than when we logged them. Papers as they published, trials starting and finishing, programme milestones, and the news coverage around them, grouped by week.
Browse by year
Week of 19 November 2007
This randomised, double-blind, active placebo-controlled, cross-over study (n=22) investigated the effects of daytime ayahuasca (DMT 70mg/70kg) consumption on sleep parameters, compared with active placebo (20mg d-amphetamine). Results showed that daytime serotonergic psychedelic drug administration leads to measurable changes in PSG and sleep power spectrum and suggest an interaction between these drugs and brain circuits modulating REM- and SWS- sleep.
AyahuascaHealthy VolunteersNeuroimaging & Brain Measures
Week of 1 October 2007
As of May 21st, 2012, the purpose of this study is to test the antidepressant effect of ketamine when given repeatedly over a period of 1 week, as well as the use of Lithium as a relapse-prevention strategy for patients with treatment-resistant depression (TRD) who respond to an initial series of ketamine infusions.
Ketamine
Week of 24 September 2007
Randomised, placebo-controlled parallel-group multi-centre trial (n=100; withdrawn) testing a single IV ketamine infusion (0.5 mg/kg over 40 minutes) versus saline placebo in treatment-resistant major depression.
Ketamine
Week of 10 September 2007
This double-blind, placebo-controlled crossover study (n=10) investigated the effects of psilocybin (215 μg/kg) with and without the 5-HT2A antagonist ketanserin on binocular rivalry. It finds that psilocybin reduced the rate of perceptual switching, an effect that was not blocked by ketanserin despite the antagonist preventing other positive psychotic-like symptoms.
LSDPsilocybinSchizophreniaHealthy VolunteersRandomised, single-blind, placebo-controlled crossover study (n=12) assessing IV S(+)-ketamine PK/PD and experimental analgesia in healthy volunteers.
Ketamine
Week of 27 August 2007
This ethnographic study (2007) of ibogaine use (n=3414, estimated users) finds that it is mostly being used for opioid withdrawal (53%). The study also identifies four different types of use (medical, lay provider, self-help, religious).
IbogaineSubstance Use Disorders (SUD)
Week of 16 July 2007
This review (2007) discusses the behavioural pharmacology of phenethylamine (MDMA), tryptamine (psilocybin, DMT), and ergoline (LSD) hallucinogens.
MDMAPsilocybinDMTLSDMedicinal Chemistry & Drug Development
Week of 25 June 2007
This double-blind placebo-controlled study (2007; n=9) investigated state and trait anxiety, hopelessness, and panic under the acute influence of ayahuasca in long-term users. Results show decreases in hopelessness and panic, but no change in anxiety.
AyahuascaAnxiety Disorders
Week of 28 May 2007
This comparative study on 2,5-Dimethoxy-4-substituted phenylisopropylamines and phenethylamines examines their activity as serotonin 5-HT2A/2C agonists. It finds that phenylisopropylamines generally exhibit higher efficacy than phenethylamines at the 5-HT2A receptor, but both act as partial agonists at the 5-HT2C receptor. The research highlights differential activation of phospholipase C (PLC) and phospholipase A2 (PLA2) pathways by these compounds in cell-based assays, with phenylisopropylamines showing stronger efficacy as head shake inducers in rats, supporting the concept of functional selectivity in receptor signaling pathways.
2C-X
Week of 21 May 2007
Randomised, triple-blind Phase II trial (n=12) comparing two sessions of full-dose MDMA-assisted psychotherapy (125 mg + 62.5 mg supplemental) versus low-dose active placebo MDMA (25 mg + 12.5 mg) for chronic PTSD.
MDMA
Week of 26 March 2007
Randomised, quadruple-blind, crossover trial (n=56) in adults with cancer-related anxiety/depressive symptoms testing two oral psilocybin sessions (low vs high dose) as supportive care.
Psilocybin
Week of 26 February 2007
This open-label longitudinal study (n=59) investigated the efficacy of a single versus three sessions of ketamine-assisted psychotherapy (140mg/70kg/session) for people with heroin dependence and found that the three-session program is more than twice as effective (abstinence 50% vs. 22.2%) one year after treatment.
KetamineAnxiety DisordersDepressive DisordersOpioid Use Disorder (OUD)Substance Use Disorders (SUD)
Week of 12 February 2007
This double-blind, placebo-controlled, randomised, counterbalanced, within-subjects study (n=16) investigated the effects of psilocybin (8, 15, & 22mg/70kg) on prepulse inhibition, and found that it inhibited this startle reflex at short interstimulus intervals in a dose-dependent manner. Results indicated the impairment of attention and an inability to filter out unnecessary sensory information under the influence of psilocybin that is similar to patients with schizophrenia.
PsilocybinSchizophreniaHealthy Volunteers
Week of 29 January 2007
Pilot randomised, triple-blind Phase II study testing MDMA-assisted psychotherapy in people with advanced-stage cancer and anxiety; Stage 1 randomised (full vs low MDMA doses) with optional Stage 2 open-label extension.
MDMAThis study (2007) identifies the biological reasons, the specific regulation of Gi/o proteins and Src, why psychedelics that affect the 5-HT2A receptor have hallucinogenic effects while agonists (lusuride) do not.
LSDMescaline
Week of 1 January 2007
In a double‑blind, dose‑dependent study, psilocybin impaired temporal reproduction and sensorimotor synchronisation for intervals longer than roughly 2–3 seconds and slowed preferred tapping rate, alongside working‑memory deficits and increased reports of depersonalisation/derealisation. These findings implicate 5‑HT2A/1A‑mediated disruption of duration processing for longer intervals and voluntary control of movement speed, and represent the first systematic demonstration of psilocybin’s selective effects on temporal processing.
DMTPsilocybinHealthy Volunteers
Showing 16 of 16 in 2007